286 related articles for article (PubMed ID: 11987924)
1. Minimal residual disease monitoring in multiple myeloma.
Davies FE; Rawstron AC; Owen RG; Morgan GJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
[TBL] [Abstract][Full Text] [Related]
2. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
3. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
[TBL] [Abstract][Full Text] [Related]
12. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
[TBL] [Abstract][Full Text] [Related]
13. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
14. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in myeloma: are we there yet?
Hart AJ; Jagasia MH; Kim AS; Mosse CA; Savani BN; Kassim A
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1790-9. PubMed ID: 22626785
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease detection in myeloma: no more molecular remissions?
Rawstron AC
Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557
[No Abstract] [Full Text] [Related]
17. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M; Badbaran A; Fehse B; Bacher U; Zander AR; Kröger NM
Bone Marrow Transplant; 2008 May; 41(10):913-6. PubMed ID: 18264143
[No Abstract] [Full Text] [Related]
18. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.
Voena C; Malnati M; Majolino I; Fagà G; Montefusco V; Farina L; Santoro A; Ladetto M; Boccadoro M; Corradini P
Bone Marrow Transplant; 2003 Oct; 32(8):791-3. PubMed ID: 14520423
[TBL] [Abstract][Full Text] [Related]
19. [Immunoglobulin heavy chain gene rearrangements in the monoclonal gammopathies].
Bosaleh A; Denninghoff V; Garcia A; Rescia C; Avagnina A; Elsner B
Medicina (B Aires); 2005; 65(3):219-25. PubMed ID: 16042132
[TBL] [Abstract][Full Text] [Related]
20. Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients.
Rimelen V; Ferrand C; Debecker A; Sovalat H; Tancredi C; Eidenschenk A; Hénon P
Leukemia; 2005 Mar; 19(3):492-5. PubMed ID: 15625553
[No Abstract] [Full Text] [Related]
[Next] [New Search]